Developer Applies for Use of CAR T-Cell Therapy in DLBCL – Cancer Network
The Pharma Letter |
Developer Applies for Use of CAR T-Cell Therapy in DLBCL
Cancer Network The pharmaceutical company Novartis has submitted an application to the US Food and Drug Administration (FDA) to extend the indications for its chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah). The application is for its use in … Novartis files for approval of its new CAR–T cell therapy in Europe Novartis files CAR–T in Europe in broader use than Gilead rival Novartis files CAR–T therapy in Europe |
